Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Enhertu (trastuzumab deruxtecan) and Lynparza (olaparib) for breast cancer settings.
Enhertu is being jointly developed and commercialized by AstraZeneca Plc AZN and Daiichi Sankyo DSNKY.
Lynparza is jointly developed and commercialized by AstraZeneca and Merck & Co Inc MRK.
Ipsen Buys Epizyme To Bolster Cancer Portfolio
Ipsen SA IPSEY IPSEF has agreed to acquire Epizyme Inc EPZM at $1.45 per share for approximately $247 million plus one contingent value right (CVR) per share.
Each CVR entitles deferred cash payments of 30 cents payable upon the first achievement of $250 million in sales of Tazverik in any period of four consecutive quarters by 2026.
An additional 70 cents per CVR is payable upon FDA approval for Tazverik and R2 combo in second-line follicular lymphoma by Jan. 1, 2028.
Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response
Pfizer Inc PFE and BioNTech SE BNTX said the modified vaccine against the omicron coronavirus variant generated a higher immune response.
The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a 13.5- and 19.6-fold increase in neutralizing geometric titers against that subvariant.
Axsome Gains On Proposed FDA Labeling For Depression Candidate
Axsome Therapeutics Inc AXSM received from the FDA proposed labeling for the company's AXS-05 marketing application for major depressive disorder.
The company is reviewing the proposed labeling and will reply to the FDA to secure a final labeling agreement.
Shares are up 39.8% at $34.19 during the premarket session.
FDA Institutes Partial Hold On Nuvation Bio's Early Stage Solid Tumor Trial
The FDA has placed a partial clinical hold on Nuvation Bio Inc's NUVB Phase 1 dose-escalation study of NUV-422 in solid tumors.
Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the company paused the enrollment of new patients to assess these adverse events further.
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
The FDA has placed a clinical hold on Astellas Pharma Inc's ALPMY FORTIS Phase 1/2 trial following a serious adverse event of peripheral sensory neuropathy in one of the trial participants.
FORTIS trial is evaluating AT845, an investigational adeno-associated virus gene replacement therapy in adults with Late-Onset Pompe Disease.
Stealth BioTherapeutics Receives Preliminary Buyout Proposal
Stealth BioTherapeutics Corp MITO has received a preliminary non-binding proposal letter from Morningside Venture Investments Ltd and J. Wood Capital Advisors LLC to acquire the company for $0.026/share and $0.313/ADS.
GSK Shares Encouraging Data From Chronic Hepatitis B Candidate
GSK plc GSK announced promising interim results from the B-Clear Phase 2b trial of bepirovirsen in people with chronic hepatitis B.
The data showed that bepirovirsen reduced hepatitis B surface antigen levels and hepatitis B virus DNA after 24 weeks of treatment.
Hillstream BioPharma Collaborates With Sapien Biosciences For Cancer Treatments
Hillstream BioPharma Inc HILS has collaborated with Sapien Biosciences to evaluate the synergy of HSB-1216 with immune checkpoint inhibitors.
"We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology, and Immune-oncology," said Dr. Jugnu Jain, CEO, Sapien Biosciences. "Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple-negative breast cancer cells presented at AACR 2020."
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.